Linaprazan glurate

戊二酸利那拉生酯

Report date: 2026/03/26 20:00:17
NME

Base Information

Drug NameLinaprazan glurate
Drug Alias Name信诺拉生酯信立安X-842X842SND-001 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPotassium-transporting ATPase inhibitors
TargetsPotassium-transporting ATPase
Therapy Area/IndicationsHelicobacter pylori infectionStomach UlcerDuodenal Ulcer +[6] 
Global Approved IndicationsEsophagitis, Peptic
Approved Indications in ChinaEsophagitis, Peptic
Original Approved Country/TerritoryMainland China
Original Approved Date2024/12/01
Country/TerritoryCzechiaBulgariaUnited States +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca Plc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Shengnuo Pharmaceutical Technology Co LtdCinclus PharmaCinclus Pharma Ag +[6] 
Inactive CompaniesN/A
Active IndicationsHelicobacter pylori infectionStomach UlcerDuodenal Ulcer +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A